Galmed Pharma (GLMD) Updates on 'At-The-Market' Financing Program; Says ~$5M Raised
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) announced that, to date, it has raised approximately $5.0 million under the Company's At-The-Market financing executed by Cantor Fitzgerald (the "ATM"). In total, to date the Company has issued 933,160 ordinary shares under the ATM at an average sale price of $5.11 per share.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Theravance Biopharma (TBPH) Announces $100M Shares, $150M Conv. Stock Offerings
- Buckeye Partners (BPL) Sells More Units
- Cantor Fitzgerald Defends Corbus Pharmaceuticals (CRBP) Following Short Report
Create E-mail Alert Related CategoriesCorporate News, Equity Offerings
Related EntitiesCantor Fitzgerald
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!